ProMIS Neurosciences Presents Data From PMN310 Phase1a Clinical Trial At The 17th Clinical Trials On Alzheimer's Disease Conference; Results Indicated PMN310 Was Generally Well-Tolerated And Monthly Dosing Can Provide CSF Levels Adequate For Target...

Benzinga10/30 20:10

ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now

Yahoo Finance10/14 02:58

ProMIS Neurosciences Director Shafmaster Purchases $255,750 in Stock

Investing09/25 06:58

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying

Benzinga09/19 21:17

Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket

Benzinga09/19 17:26

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish From Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

Yahoo Finance09/12 19:00